Physician profile
George J Walker
NPI 1528053121
$14,513.16
in general payments reported to CMS, 2019-2025
44 companies · $2,730 in 2025
The $2,730 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,027 · 2020: $1,111 · 2021: $2,061 · 2022: $2,416 · 2023: $2,621 · 2024: $2,547 · 2025: $2,730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,761 · Education: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,761.33 |
| Education | $136.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,391.23 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $1,115.32 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $1,076.82 | 2019-2025 | Stelara, Tremfya, Remicade |
| Pfizer INC. | $1,018.39 | 2019-2025 | |
| Gilead Sciences, INC. | $996.01 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $697.51 | 2019-2024 | Rebyota, Cimzia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $587.64 | 2019-2025 | Xifaxan, Relistor |
| Merck Sharp & Dohme LLC | $472.04 | 2019-2024 | Dificid |
| Ipsen Biopharmaceuticals, INC | $357.71 | 2024-2025 | Iqirvo |
| Genzyme Corporation | $334.00 | 2023-2025 | |
| Daiichi Sankyo INC. | $326.05 | 2019-2023 | Injectafer |
| Celgene Corporation | $308.95 | 2021-2024 | Zeposia |
| Qol Medical, LLC | $308.84 | 2019-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $288.80 | 2022-2025 | Dupixent |
| Ardelyx, INC. | $253.92 | 2022-2025 | Ibsrela |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $243.78 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $215.10 | 2019-2024 | Linzess |
| Intercept Pharmaceuticals, INC. | $194.45 | 2019-2025 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $141.75 | 2021-2023 | |
| Organon LLC | $131.20 | 2022-2024 | Renflexis, Hadlima |
| Lilly USA, LLC | $113.72 | 2023-2025 | Omvoh |
| Amgen INC. | $108.27 | 2021-2023 | Avsola, Amjevita |
| Glaxosmithkline, LLC. | $103.60 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $71.74 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $66.14 | 2025 | Zenpep |
| Redhill Biopharma INC. | $65.50 | 2020-2021 | |
| Ucb, INC. | $58.50 | 2019-2020 | |
| Shionogi INC | $55.20 | 2019-2020 | |
| Capsovision, INC. | $50.02 | 2023-2024 | Capsocam Plus |
| Medtronic, INC. | $48.99 | 2022-2024 | Interstim |
| Endo Pharmaceuticals INC. | $42.67 | 2020 | |
| Shire North American Group INC | $38.68 | 2019 | |
| Braintree Laboratories, INC. | $36.90 | 2019-2025 | Suflave, Sutab |
| Fresenius Kabi USA, LLC | $28.71 | 2023 | |
| Orphalan INC | $23.72 | 2025 | Cuvrior |
| Allergan, INC. | $23.55 | 2019 | |
| Biocon Biologics INC | $21.96 | 2025 | Yesintek |
| Pharmacosmos Therapeutics INC. | $18.99 | 2025 | Monoferric |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.36 | 2024 | Cyltezo |
| Pentax of America, INC. | $16.44 | 2022 | |
| Celltrion USA INC. | $15.21 | 2023 | Yuflyma |
| Axonics, INC. | $14.89 | 2021 | |
| Medline Industries LP | $12.89 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$52,173.81 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.